Inhaled Mometasone Furoate

Sharpe, Miriam; Jarvis, Blair

doi:10.2165/00003495-200161090-00011

Cited by 55 publications

(2 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MF dry powder inhaler has been demonstrated to have an excellent safety and efficacy profile, and during post-marketing surveillance and in clinical trials no significant adverse side effects have been reported. In addition, its simple use seems to improve asthma management by addressing issues that generally inhibit proper adherence to therapy [ 35 – 38 ]. These considerations for the usage of MF in asthma could be extended to MF administered via the intranasal route.…”

Section: Main Textmentioning

confidence: 99%

Mometasone furoate nasal spray: a systematic review

Passàli

Spinosi

Crisanti

et al. 2016

Multidiscip Respir Med

View full text Add to dashboard Cite

The inflammatory diseases of the nose, rhino-pharynx and paranasal sinuses (allergic and non allergic rhinitis, NARES; rhinosinusitis with/without nasal polyposis, adenoidal hypertrophy with/without middle ear involvement) clinically manifest themselves with symptoms and complications severely affecting quality of life and health care expenditure.Intranasal administration of corticosteroids, being fast, simple, and not requiring cooperation, is the preferred way to treat the patients, to optimize their quality of life, at the same time minimizing the risk of exacerbations and complications.Among the different topical steroids available on the market, we performed a comparative analysis in terms of effectiveness and safety between mometasone furoate (MF) and its main competitors.Searching through Pub Med and Google Scholar and using as entries “mometasone furoate”, “rhinitis”, “sinusitis”, “asthma”, “polyposis”, “otitis media with effusion”, and “adenoid hypertrophy” we found 344 articles, 300 of which met the eligibility criteria.Taking into account relevance and date of publication, a sample of 40 articles was considered for the review.MF effectiveness for treatment and/or prophylaxis of nasal symptoms in seasonal and perennial allergic rhinitis has been fully established with a level of evidence Ia.Even though it has not been assessed for MF in particular, topical steroids are the most appropriate treatment in mixed rhinitis and NARES.In acute rhinosinusitis (ARS) evidences support their use as mono-therapy or as adjuvant to antibiotics for reducing the recurrence rate, and decrease the usage of related prescriptions and medical consultations.In chronic rhinosinusitis (CRS) with Nasal polyposis, MF reduces polyps size, nasal congestion, improves quality of life and sense of smell and it is also effective in the treatment of daytime cough.The topical use of MF has great efficacy in the management of adenoidal hypertrophy and otitis media of atopic children.As regards the safety, MF has demonstrated an excellent safety profile: pregnant women can safely use it; no systemic effects on growth velocity and adrenal suppression have been shown; no changes in epithelial thickness or atrophy have been observed after long term administration of the drug.Conclusions: MF has been demonstrated to be effective in the treatment of the inflammatory diseases of the nose and paranasal sinuses; when compared to its competitors it shows a greater symptom control; it is a reliable treatment in the long term thanks not only to its proven efficacy, but also to its safety being on the market since more than 17 years.

show abstract

Section: Main Textmentioning

confidence: 99%

Mometasone furoate nasal spray: a systematic review

Passàli

Spinosi

Crisanti

et al. 2016

Multidiscip Respir Med

View full text Add to dashboard Cite

show abstract

“…Receptor affinity is usually measured relative to dexamethasone. Of the currently available compounds, mometasone has the highest relative receptor affinity, followed by fluticasone and the active metabolites of beclomethasone (17-BDP monopropionate) and ciclesonide (des-CIC) (12, 13, 14). …”

Section: Inhaled Corticosteroidsmentioning

confidence: 99%

The Paradoxical Effect on Pneumonia of Chronic Inhaled Corticosteroids

Sibila¹,

Anzueto²,

Restrepo³

2013

Clinical Pulmonary Medicine

View full text Add to dashboard Cite

Community-acquired pneumonia (CAP) is the leading infectious cause of death in developed countries. Several studies have shown that the risk of pneumonia is increased in patients with Chronic Obstructive Pulmonary Disease (COPD) who are receiving chronic inhaled corticosteroids (ICS). The impact of ICS On pneumonia prognosis is controversial. Recent studies have shown that COPD patients with prior ICS use have less mortality after developing CAP as compared with patients with COPD without prior ICS use. This review discusses the association of ICS and the risk of CAP and its association with clinical outcomes in patients with COPD and pneumonia.

show abstract

Mometasone furoate degradation and metabolism in human biological fluids and tissues

Teng

Cutler

Davies

2003

Biopharm & Drug Disp

View full text Add to dashboard Cite

The in vitro metabolic and non-metabolic degradation kinetics of mometasone furoate (MF) was investigated in selected human biological fluids and subcellular fractions of tissues. Qualitative and quantitative differences in transformation profiles of MF were observed among human biological media. Degradation was the major event in plasma and urine with four new degradation products identified; A: 21-chloro-17alpha-hydroxy-16alpha-methyl-9beta,11beta-oxidopregna-1,4-diene-3,20-dione 17-(2-furoate), B: 9alpha,21beta-dichloro-11beta,21alpha-dihydroxy-16alpha-methylpregna-1,4,17,20-tetraen-3-one 21-(2-furoate), C: 21beta-chloro-21alpha-hydroxy-16alpha-methyl-9beta,11beta-oxidopregna-1,4,17,20-tetraen-3-one 21-(2-furoate), and D: 21-chloro-17alpha-hydroxy-16alpha-methyl-9beta,11beta-oxidopregna-1,4-diene-3,20-dione. A, B and C were predominant and D was minor in plasma while A and C were predominant in urine. Hydrolysis of the 17-ester bond of MF was not a major event in plasma. The turnover of MF in plasma was faster than that in phosphate buffers of pH 7.4. Metabolism of MF occurred primarily and rapidly in liver, appreciably in intestine, but negligibly in in vitro lung tissue. While 6beta-hydroxylation was a major metabolic pathway for MF in microsomes of both human liver and intestine, other parallel and subsequent metabolism pathways could also be involved. If these degradation and metabolic products are also formed and active in humans in vivo, both MF and its 'active' products need to be taken into account when determining the systemic bioavailability of MF and in establishing concentration-effect relationships with this drug.

show abstract

Inhaled Mometasone Furoate

Cited by 55 publications

References 62 publications

Mometasone furoate nasal spray: a systematic review

Mometasone furoate nasal spray: a systematic review

The Paradoxical Effect on Pneumonia of Chronic Inhaled Corticosteroids

Mometasone furoate degradation and metabolism in human biological fluids and tissues

Contact Info

Product

Resources

About